-
2 weeks ago | 
nature.com | Jayastu Senapati |Guillermo Garcia-Manero |Courtney DiNardo |Gautam Borthakur |Tapan M Kadia |Elias Jabbour | +8 more
Despite the improvement in overall outcomes of patients with acute myeloid leukemia (AML), some high-risk disease subsets continue to fare dismally. AML with TP53 aberrations (mutations, deletions) is one such subset of high-risk AML with a median survival of about 6–9 months [1,2,3].
-
3 weeks ago | 
nature.com | Mahesh Swaminathan |Courtney DiNardo |Naveen Pemmaraju |Guillermo Garcia-Manero |Ghayas C. Issa |Gautam Borthakur | +9 more
To the Editor:The advent of VEN (VEN) has changed the treatment paradigm of acute myeloid leukemia (AML). Currently, venetoclax (VEN), in combination with a hypomethylating agent (HMA), is approved for the treatment of adult patients with AML unsuitable for intensive chemotherapy or frontline treatment of patients ≥75 years [1].
-
1 month ago | 
nature.com | Courtney DiNardo |Wei-Ying Jen |Koichi Takahashi |Tapan M Kadia |Sanam Loghavi |Patrick K. Reville | +19 more
AbstractIntensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax.
-
Jan 6, 2025 | 
onlinelibrary.wiley.com | Hagop Kantarjian |Nicholas Short |NITIN JAIN |Fadi Haddad |Tapan Mahendra Kadia |Musa Yilmaz | +8 more
Conflicts of Interest H.K. received research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, Astra Zeneca, Ipsen, Pharmaceuticals, KAHR Medical Ltd., NOVA Research, Novartis, Pfizer, Precision Biosciences, and Taiho Pharmaceutical Canada.
-
May 20, 2024 | 
cancernetwork.com | Rahul Gosain |Rohit Gosain |Naveen Pemmaraju
2 Commerce Drive Cranbury, NJ 08512
-
Mar 6, 2024 | 
cancernetwork.com | Fiza Khan |Foorquan Hashmi |Nerses Ghahramanyan |Elen Baloyan |Gevorg Tamamyan |Marina Konopleva | +2 more
March 6, 2024OncologyONCOLOGY Vol 38, Issue 3Pages: 104-106A recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting. ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting.
-
Dec 11, 2023 | 
healio.com | Matthew Shinkle |Drew Amorosi |Lee Greenberger |Naveen Pemmaraju
You've successfully added Hematology Oncology: Myeloproliferative Neoplasms to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Navitoclax plus ruxolitinib led to improvement in spleen volume reduction in patients with untreated myelofibrosis.
-
Jun 14, 2023 | 
fal.cn | Naveen Pemmaraju
Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of introducing pacritinib (Vonjo) to the treatment paradigm for patients with myelofibrosis with low platelet counts.
-
Jun 14, 2023 | 
onclive.com | Naveen Pemmaraju
Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of introducing pacritinib (Vonjo) to the treatment paradigm for patients with myelofibrosis with low platelet counts.
-
Feb 2, 2023 | 
onclive.com | Naveen Pemmaraju
OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications
